In a patient with atrial fibrillation and reduced ejection fraction of 47%, should rate control be achieved with a beta‑blocker or digoxin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Beta-Blocker is the Preferred First-Line Agent for Rate Control

In a patient with atrial fibrillation and an ejection fraction of 47% (reduced LVEF), a beta-blocker should be the primary choice for rate control, with digoxin reserved as an adjunctive agent if rate control remains inadequate or if beta-blockers are contraindicated.

Rationale Based on Guidelines

The 2014 AHA/ACC/HRS guidelines provide clear direction for this clinical scenario. With an EF of 47%, this patient has heart failure with reduced ejection fraction (HFrEF), defined as LVEF <50% in most contexts. The guidelines make a Class I recommendation that intravenous beta-blocker administration is recommended to slow ventricular response in AF in the acute setting, though caution is needed in patients with overt congestion, hypotension, or HF with reduced LVEF 1, 2.

For chronic management, the guidelines specify that digoxin is effective to control resting heart rate in patients with HF with reduced EF (Class I, Level of Evidence C) 1. However, this does not make it first-line. The guidelines also state that a combination of digoxin and a beta-blocker is reasonable to control resting and exercise heart rate (Class IIa, Level of Evidence B) 1, 2.

The most recent 2024 ESC guidelines reinforce this approach: beta-blockers and/or digoxin are recommended in patients with AF and LVEF ≤40% to control heart rate and reduce symptoms (Class I, Level of Evidence B) 3. Notably, beta-blockers are listed first, and the conjunction "and/or" suggests beta-blockers should be initiated first.

Why Beta-Blockers Take Priority

Mortality and Morbidity Benefits

Beta-blockers provide prognostic benefits in HFrEF beyond rate control alone. They reduce mortality and heart failure hospitalizations in patients with systolic dysfunction, regardless of rhythm. While recent evidence suggests the mortality benefit may be attenuated in HFrEF patients with AF compared to sinus rhythm 4, beta-blockers still offer cardiovascular protection that digoxin does not provide.

Exercise Rate Control

Digoxin is primarily effective for resting heart rate control but performs poorly during exercise or stress 5, 6. The FDA label confirms digoxin is indicated for rate control but does not specify superiority over other agents 7. Beta-blockers provide rate control both at rest and during activity, which is clinically more relevant for symptomatic patients 1, 8.

Safety Profile in Reduced EF

The guidelines explicitly note caution with beta-blockers in patients with "overt congestion, hypotension, or HF with reduced LVEF" 2, but this is a caution about acute administration and dosing—not a contraindication. Beta-blockers should be initiated at low doses and titrated carefully in stable HFrEF patients.

Digoxin, conversely, has a narrow therapeutic window and requires monitoring of serum levels, renal function, and electrolytes 9, 7. The FDA label warns about toxicity risks, particularly in patients with renal impairment, and notes that digoxin may worsen outcomes in certain HF populations with preserved EF 7.

Recent Evidence: The RATE-AF Trial

The 2020 RATE-AF trial compared low-dose digoxin versus bisoprolol in patients with permanent AF and heart failure symptoms 10. Key findings:

  • No significant difference in quality of life (primary outcome) at 6 months
  • Digoxin had fewer adverse events (25% vs 64%, p<0.001)
  • Digoxin improved symptom scores (modified EHRA class) more than bisoprolol
  • No difference in resting heart rate control between groups

The 2025 follow-up echocardiographic analysis showed that low-dose digoxin improved systolic function more than beta-blockers in patients with preserved EF (≥50%) 11, but this patient has reduced EF at 47%.

However, a 2025 target trial emulation from Hong Kong involving 28,377 patients with coexisting AF and HF found that digoxin was associated with significantly higher risks of all-cause mortality (RR 1.21), CV mortality (RR 1.20), and HF hospitalization (RR 1.10) compared to beta-blockers 12. This large observational study reinforces guideline recommendations favoring beta-blockers.

Clinical Algorithm for This Patient

Step 1: Assess Hemodynamic Stability

  • If hemodynamically unstable or acutely decompensated: Use IV digoxin or amiodarone for acute rate control (Class I) 1, 2
  • If stable: Proceed with oral beta-blocker initiation

Step 2: Initiate Beta-Blocker

  • Start with a low dose (e.g., metoprolol succinate 12.5-25 mg daily, carvedilol 3.125 mg twice daily, or bisoprolol 1.25 mg daily)
  • Titrate slowly every 2-4 weeks as tolerated
  • Target resting heart rate <100 bpm (lenient control) or <80 bpm (strict control) based on symptoms 1, 5

Step 3: Assess Response at 4-6 Weeks

  • If adequate rate control achieved and patient tolerates beta-blocker: Continue monotherapy
  • If inadequate rate control despite maximally tolerated beta-blocker dose: Add digoxin (Class IIa) 1, 2, 6

Step 4: Consider Digoxin as First-Line Only If:

  • Hypotension precludes beta-blocker use
  • Absolute contraindication to beta-blockers (e.g., severe reactive airway disease, though cardioselective beta-blockers may still be considered)
  • Patient is elderly and sedentary with primarily resting symptoms 8, 6

Step 5: Combination Therapy

If monotherapy with beta-blocker fails:

  • Add digoxin 0.125-0.25 mg daily (lower dose in elderly, renal impairment, or low body weight) 7
  • Monitor serum digoxin levels (target 0.5-0.9 ng/mL) 5, 9
  • Check renal function and electrolytes regularly 9, 7

Common Pitfalls to Avoid

  1. Using digoxin as sole agent in younger or active patients: Digoxin fails to control exercise heart rate and guidelines recommend against it as monotherapy in paroxysmal AF 6

  2. Avoiding beta-blockers entirely due to reduced EF: While caution is warranted, beta-blockers are indicated in HFrEF and should be initiated at low doses in stable patients

  3. Over-reliance on observational digoxin safety data: Much of the mortality concern with digoxin reflects confounding by indication and high serum levels. Low-dose digoxin (serum levels 0.5-0.9 ng/mL) appears safer 5, 13

  4. Ignoring non-dihydropyridine calcium channel blockers: Diltiazem and verapamil are contraindicated in HFrEF due to negative inotropic effects 1, 2, 14

  5. Failing to assess rate control during exercise: Resting heart rate alone is insufficient; symptomatic patients need exercise testing to ensure adequate rate control during activity 1, 2

Summary of Recommendation

Start with a beta-blocker (low dose, titrate slowly) as first-line therapy for rate control in this patient with AF and EF 47%. Add digoxin if beta-blocker monotherapy at maximally tolerated doses fails to achieve adequate rate control or if beta-blockers are contraindicated due to hypotension or other absolute contraindications. This approach aligns with Class I guideline recommendations 1, 2, 3 and is supported by the most recent large-scale observational evidence showing superior outcomes with beta-blockers 12.

References

Related Questions

In a patient with heart failure and atrial fibrillation who complains of palpitations, which medication is appropriate for rate control: digoxin, labetalol, or carvedilol?
For a patient with atrial fibrillation, asthma, and heart failure, should digoxin be administered orally as the chronic rate‑control agent?
Can a patient with atrial fibrillation, impaired renal function (GFR 40 mL/min), normal potassium, hypotension (mean arterial pressure 63 mmHg), and tachycardia (heart rate 140 bpm) be safely loaded with digoxin?
How should digoxin and a beta‑blocker be initiated and titrated for rate control in an adult with heart failure and atrial fibrillation?
In an elderly patient with known heart failure presenting with palpitations and atrial fibrillation, without dyspnea, orthopnea, paroxysmal nocturnal dyspnea, or peripheral edema, what is the most appropriate initial treatment: propranolol, digoxin, furosemide, or dobutamine?
What are the possible causes for a woman with recurrent cutaneous eruptions, asthma, an idiosyncratic reaction to non‑steroidal anti‑inflammatory drugs (NSAIDs), marked peripheral eosinophilia, and unexplained hyperkalaemia despite normal renal function and imaging?
Does co‑trimoxazole (trimethoprim‑sulfamethoxazole) cause worsening of renal function in a patient with chronic kidney disease and an estimated glomerular filtration rate of 12 mL/min?
How should tenofovir disoproxil fumarate (TDF)–induced elevation in serum creatinine be evaluated and managed?
What is the antibiotic of choice for treating a scrotal pyocele (possible abscess) in an adult male?
In a 49-year-old man with severe multivessel coronary artery stenoses, how does plaque rupture lead to acute arterial occlusion?
Why was coronary artery bypass grafting (CABG) not performed earlier in this patient presenting with an acute plaque‑rupture coronary event?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.